Skip to main navigation
Skip to search
Skip to main content
Albert Einstein College of Medicine Home
Search content at Albert Einstein College of Medicine
Home
Faculty
Departments
Grants
Publications
Prizes
Preventive Treatment of Migraine
Richard B. Lipton
Neurology
Research output
:
Contribution to journal
›
Review article
›
peer-review
10
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Preventive Treatment of Migraine'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Acute Treatment
42%
Atogepant
28%
Calcitonin Gene-related Peptide
71%
Calcitonin Gene-related Peptide Receptor Antagonist
14%
Chronic Migraine
14%
Disability
14%
Drug Target
14%
Episodic Migraine
28%
Eptinezumab
14%
Erenumab
14%
Evidence of Effectiveness
14%
Fremanezumab
14%
Galcanezumab
14%
Gepants
14%
Good Safety
14%
Headache
14%
Health-related Quality of Life
14%
Interictal Burden
14%
Medication Overuse
14%
Migraine
14%
Migraine Medication
14%
Migraine Treatment
100%
Monoclonal Antibody
42%
Novel Paradigm
14%
Oral Small Molecules
14%
Peptide Target
42%
Preventive Migraine Treatment
14%
Preventive Treatment
100%
Rimegepant
14%
Self-efficacy
14%
Self-health
14%
Targeted Medication
14%
Targeted Therapy
28%
Tolerability
28%
Ubrogepant
28%
Zavegepant
28%
Medicine and Dentistry
Atogepant
25%
Calcitonin Gene Related Peptide
62%
Calcitonin Gene-Related Peptide Receptor Antagonist
12%
Drug Targeting
12%
Episodic Migraine
25%
Eptinezumab
12%
Erenumab
12%
Fremanezumab
12%
Galcanezumab
12%
Headache
12%
Medication Overuse
12%
Migraine
100%
Monoclonal Antibody
37%
Oral
12%
Quality of Life
12%
Rimegepant
12%
Self Concept
12%
Targeted Therapy
25%
Transformed Migraine
12%
Ubrogepant
25%
Pharmacology, Toxicology and Pharmaceutical Science
Atogepant
25%
Calcitonin Gene Related Peptide
62%
Calcitonin Gene Related Peptide Receptor Antagonist
12%
Drug Delivery System
12%
Episodic Migraine
25%
Eptinezumab
12%
Erenumab
12%
Fremanezumab
12%
Galcanezumab
12%
Headache
12%
Medication Overuse
12%
Migraine
100%
Monoclonal Antibody
37%
Rimegepant
12%
Tolerability
25%
Transformed Migraine
12%
Ubrogepant
25%